RCPCH-BPSU webinar series: Type 2 Diabetes in Children and Young People

There is growing evidence that the increase in childhood obesity has resulted in cases of Type 2 diabetes being diagnosed in younger age groups.Although the incidence of Type 2 diabetes is increasing, the condition is still relatively rare in children, and therefore the symptoms and clinical presentation of it in children may not always be clear to paediatricians who have not encountered the disease in children before. This can cause late and misdiagnoses of the condition and this often causes additional emotional and financial burdens on the patients and their families.

In this webinar, Prof Julian Hamilton-Sheild and Prof Timothy Barrett will present the findings of the 2015-16 BPSU study.
Date: -
Time: -

Free to attend

Novo Nordisk has provided a grant to the Royal College of Paediatrics and Child Health to support the creation, development and delivery of this webinar. Novo Nordisk has had no influence over the webinar's content and full editorial control remains the responsibility of the RCPCH.


Professor Julian Hamilton-Sheild,  Professor of Diabetes and Metabolic Endocrinology/Paediatrician

Julian is Professor of Diabetes and Metabolic Endocrinology and trained at Bristol and the Hospitals for Sick Children, London. He has been an honorary consultant paediatrician at Bristol Royal Hospital for Children since 1997. His main research interests encompass neonatal glucose metabolism, childhood obesity and its treatment, diabetes mellitus and the development of insulin resistance through childhood. He is a theme lead for 'Optimising nutrition to improve the health of children with chronic disorders' within the Biomedical Research Unit and a member of the BRU executive group.

Professor Timothy Barrett,  Institute of Cancer and Genomic Sciences; Leonard Parsons Professor of Paediatrics and Child Health; Director, Centre for Rare Disease Studies

Timothy Barrett is Leonard Parsons Professor of Paediatrics and Child Health in the Institute of Cancer and Genomic Sciences. He is an Honorary Consultant in Paediatric Endocrinology and Diabetes and Programme Director for the Wellcome Trust Clinical Research Facility at Birmingham Children’s Hospital. Timothy is also the Director of the Centre for Rare Disease Studies (CRDS) Birmingham.

Timothy has published over 100 research papers in scientific journals as well as reviews and book chapters in the fields of paediatrics, diabetes and genetics of childhood diabetes syndromes. He has received major grants from The Medical Research Council, The Wellcome Trust, European Union Directorate General for Health and Consumer Affairs, Diabetes UK and Wellchild. 

He leads NHS national specialist commissioned services in rare diabetes syndromes, and a busy clinical practice of general diabetes, type 2 diabetes in children, and tertiary endocrinology. He is an enthusiastic teacher and communicator on the themes of genetics and monogenic diabetes, and lectures widely at national and international level. Timothy contributes to the local and national media and advises the BBC on stories relating to childhood obesity and metabolism.

Learning outcomes

  • Understanding how UK children are affected by Type 2 diabetes
  • Understanding of the causes and development of Type 2 diabetes.
  • Develop an understanding of the current issues associated with Type 2 diabetes

Benefit to delegates

  • Understanding of the causes and development of Type 2 diabetes will increase and this will improve the diagnosis and treatment for the condition in children and young people under the age of 17
  • Developing an understanding of the current issues associated with Type 2 diabetes could also help target future approaches to preventing and managing the condition


  • General Paediatricians
  • Paediatric trainees
  • Community Paediatricians
  • Paediatric Endocrionologists
  • Midwives and Health Visitors
  • GPs &  GP trainees
  • Public Health doctors
  • Dieticians

It is also suitable for an international audience, with caveats on data (which is UK & Ireland) and treatment approaches which will be most relevant to the UK context